FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study

References

• Lampertico P, Agarwal K, Berg T. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555. doi:10.1016/S0140-6736(15)61412-X
   PubMed Web of Science ®Google Scholar
• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388(10049):1081–1088. doi:10.1016/S0140-6736(16)30579-7
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet. 2010;375(9724):1419–1420. doi:10.1016/S0140-6736(09)62195-4
   PubMed Web of Science ®Google Scholar
• Wu SD, Liu LL, Cheng JL, et al. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Clin Exp Med. 2018;18(3):433–443. doi:10.1007/s10238-018-0501-x
   PubMed Web of Science ®Google Scholar
• Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773–780. doi:10.1016/j.jhep.2015.11.012
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi:10.1016/j.jhep.2015.04.006
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289–293. doi:10.1002/hep.510240201
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol. 2012;56(4):833–839. doi:10.1016/j.jhep.2011.10.017
   PubMed Web of Science ®Google Scholar
• Delong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845. doi:10.2307/2531595
   PubMed Web of Science ®Google Scholar
• Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012;57(3):541–548. doi:10.1016/j.jhep.2012.04.025
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P; The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349(9055):825–832. doi:10.1016/S0140-6736(96)07642-8
   PubMed Web of Science ®Google Scholar
• Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009;50(4):1038–1044. doi:10.1002/hep.23111
   PubMed Web of Science ®Google Scholar
• Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8(3):493–496. doi:10.1002/hep.1840080310
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok A, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Chon YE, Park JY, Myoung SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis. Am J Gastroenterol. 2017;112(6):882–891. doi:10.1038/ajg.2017.93
   PubMed Web of Science ®Google Scholar
• Kim SU, Park JY, Kim DY, et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int. 2010;4(4):673–680. doi:10.1007/s12072-010-9201-7
   PubMed Web of Science ®Google Scholar
• Enomoto M, Mori M, Ogawa T, et al. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: regression of liver stiffness during entecavir therapy. Hepatol Res. 2010;40(9):853–861. doi:10.1111/j.1872-034X.2010.00687.x
   PubMed Web of Science ®Google Scholar
• Lu M, Li J, Zhang T, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol. 2016;14(7):1044–1055. doi:10.1016/j.cgh.2016.01.009
   PubMed Web of Science ®Google Scholar
• Al-Mohri H, Murphy T, Lu Y, et al. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr. 2007;44(4):463–469. doi:10.1097/QAI.0b013e318030ff8e
   PubMed Web of Science ®Google Scholar
• Huang C, Li Q, Xu W, et al. Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection. Discov Med. 2020;29(157):119–128.
   PubMed Web of Science ®Google Scholar